| Name | Title | Contact Details |
|---|
Tom is a Connellsville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arizona Foundation for Medical Care is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Listening to your body is one thing, understanding what it is telling you is an altogether different story. Polar helps you get under the skin of your training. We put it down to a combination of expertise in sports, physiology and electronics, coupled with a deep understanding of customer needs. It`s no surprise then that we`ve been leading the way in technological innovations and heart rate monitors since 1977. And we cater for all levels of fitness by offering a comprehensive product range, along with essential support and advice. Everything from improving an athlete`s sports performance to helping people enjoy a healthier lifestyle, and aiding rehabilitation and weight management. This desire to be the best is made possible by ambitious and highly talented professionals who still believe as passionately in what we do today, as we did over 30 years ago. And our success is clear to see. Today, Polar employs 1200 people worldwide, has 26 subsidiaries globally and manages a distribution network supplying over 35,000 retail outlets in more than 80 countries. Now that`s what we call the power behind Polar.
Angela Hospice is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.